New drug duo aims to cut relapse in multiple myeloma transplant
NCT ID NCT07542418
First seen Apr 25, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This study tests whether adding thiotepa to the standard melphalan treatment before a stem cell transplant can lower the chance of cancer returning in people with multiple myeloma. About 204 adults who haven't reached full remission will be randomly assigned to get either the new combo or the standard drug alone. The main goal is to see if the relapse rate one year after transplant is lower with the new approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.